ctDNA as a prognostic factor in operable colon cancer patients: a systematic review and meta-analysis

Yekeduz E., KÖKSOY E. B., AKBULUT H., ÜRÜN Y., UTKAN G.

FUTURE ONCOLOGY, cilt.17, sa.03, ss.349-357, 2021 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Derleme
  • Cilt numarası: 17 Sayı: 03
  • Basım Tarihi: 2021
  • Doi Numarası: 10.2217/fon-2020-0671
  • Dergi Adı: FUTURE ONCOLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, CINAHL, EMBASE, MEDLINE
  • Sayfa Sayıları: ss.349-357
  • Anahtar Kelimeler: colon cancer, circulating tumor DNA, disease-free survival, minimal residual disease, CIRCULATING-TUMOR DNA, PREDICTIVE FACTORS, COLORECTAL-CANCER
  • Ankara Üniversitesi Adresli: Evet

Özet

Colon cancer is one of the most common cancer all over the world. Patients with early-stage disease are treated with surgery. However, some of these patients have a cancer recurrence risk because of residual cancer cells in their bodies after surgery. In these patients, chemotherapy is performed after surgery to reduce the recurrence risk. Despite this risk-reducing strategy, some patients do not benefit from chemotherapy. Historically, some patients and tumor characteristics have been used to determine which patients would benefit from chemotherapy. However, these indicators are not enough to make this determination. Circulating tumor DNA (ctDNA) is an emerging marker to show residual cancer cells immediately after surgery and chemotherapy. This systematic review and meta-analysis shows the effect of ctDNA on colon cancer recurrence after surgery and chemotherapy.